Currently three different types of immune checkpoint inhibitors (ICIs) are approved for the treatment of advanced melanoma: CTLA-4 inhibitor (ipilimumab), PD-1 inhibitor (pembrolizumab and nivolumab) and LAG-3 inhibitor (relatlimab) [13,28,29]. The gene discussed is PDCD1; the disease is melanoma.